Lumen Integrates with Connect IQ to Provide Garmin Users Metabolic Data to Improve Their Performance and Health
11.11.2020 13:00:00 EET | Business Wire | Press release
Lumen, the world’s first hand-held metabolic tracking device, together with Garmin® International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), have launched a Connect IQ Lumen App and Garmin Health API integration, allowing users to better understand the impact of fitness and nutrition decisions on their body in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005049/en/
Lumen and Garmin integration (Photo: Lumen)
Through the CO2 concentration in a single breath, Lumen measures your metabolic health and provides daily personalised nutrition plans and insights into what your body is burning - fats or carbs. Lumen supports fat burn and improves your metabolic flexibility, which is your body's ability to efficiently switch between using carbs and fats as a fuel source.
Garmin activity trackers and smartwatches help you track and share your activities. Thanks to Lumen data and the Garmin Health API integration, Garmin users can now seamlessly integrate their health and activity data such as heart rate, sleep, steps and calories burned, into the Lumen app and instantly optimise their fitness journey.
“We are thrilled to work with Garmin on this crucial integration. We know how important it is for our users to get valuable insights into their fitness and this will allow them to make more informed decisions about their nutrition and improve their metabolic health,” said Lumen CEO, Daniel Tal.
By combining Garmin and Lumen data, users will be able to monitor their carb fuel consumption through notifications that guide them on when to breathe into Lumen and unlock their day or take a post workout breath. Users can now see how their workout affects their metabolism through recovery macros and a comprehensive Garmin workout summary.
“Lumen is an innovative organisation pushing the boundaries on metabolic health and performance optimisation. Garmin’s Connect IQ platform will enable users to act in real-time to make the right fitness and nutrition decisions at every moment,” said Sean McNamara, Garmin Health Senior Manager Sales and Marketing.
For continual metabolic tracking, Garmin users with compatible devices will also have access to crucial Lumen data such as morning insights, daily and weekly Lumen levels and the Lumen Flex Score which indicates the degree of metabolic flexibility. The goal is to make sure that nutrition and metabolic health remain top of mind.
About Garmin Health
Engineered on the inside for life on the outside, Garmin products have revolutionised the wellness industry. Garmin Health provides enterprise solutions that leverage Garmin wearables and the high-quality sensor data they produce for applications in the corporate wellness, population health, and patient monitoring markets. For more information, visit garmin.com/health, contact the Media Relations department at 913-397-8200, or follow us at facebook.com/garmin, twitter.com/garminnews, instagram.com/garminwellness or youtube.com/garmin.
About Garmin Connect IQ
Connect IQ is the app system for Garmin wearables, bike computers, and outdoor handhelds. Connect IQ allows developers to create on-device solutions for Garmin users. Developers use the Connect IQ SDK to develop apps, and then upload their creations to the Connect IQ store. From there, millions of Garmin users can browse thousands of apps including Starbucks, Spotify, and Amazon Music for download to their Connect IQ compatible device.
About Lumen
Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.
Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month. Lumen’s vision is to improve the world's metabolic health and quality of life by empowering individuals to make smarter decisions about their nutrition and lifestyle. Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.
Follow us at twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005049/en/
Contact information
Press
press@lumen.me
+972548161939
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 23:08:00 EEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 22:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, security, and performance required for enterprise environments. These capabilities enable organizations to move from pilot to production with confiden
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recollection, and real-time business data. Lack of governance, auditability, and operational control drives up compute costs while diminishing productivity and revenue. “2026 is the year organizations move from AI experimentation to a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom